New antituberculosis drugs

From clinical trial to programmatic use

Gina Gualano, Susanna Capone, Alberto Matteelli, Fabrizio Palmieri

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensitive disease, highlighting the need for of new drugs. For the first time in more than 50 years, two new anti-TB drugs were approved and released. Bedaquiline is a first-in-class diarylquinoline compound that showed durable culture conversion at 24 weeks in phase IIb trials. Delamanid is the first drug of the nitroimidazole class to enter clinical practice. Similarly to bedaquiline results of phase IIb studies showed increased sputum-culture conversion at 2 months and better final treatment outcomes in patients with MDR-TB. Among repurposed drugs linezolid and carbapenems may represent a valuable drug to treat cases of MDR and extensively drugresistant TB. The recommended regimen for MDR-TB is the combination of at least four drugs to which M. tuberculosis is likely to be susceptible for the duration of 20 months. Drugs are chosen with a stepwise selection process through five groups on the basis of efficacy, safety, and cost. Clinical phase III trials on new regimen are ongoing that could prove transformative against MDR-TB, by being shorter (six months), simpler (an alloral regimen) and safer than current standard therapy. It is fundamental that the adoption of the new drugs is done responsibly to avoid inappropriate use. Concentration of inpatient MDR-TB treatment in specialized centers could be considered in countries with low numbers of cases in order to provide appropriate clinical case management and to prevent emergence of drug resistance.

Original languageEnglish
Pages (from-to)43-49
Number of pages7
JournalInfectious Disease Reports
Volume8
Issue number2
DOIs
Publication statusPublished - 2016

Fingerprint

Multidrug-Resistant Tuberculosis
Clinical Trials
Pharmaceutical Preparations
bedaquiline
Linezolid
Diarylquinolines
Drug Repositioning
Nitroimidazoles
Phase III Clinical Trials
Carbapenems
Poisons
Case Management
Sputum
Drug Resistance
Inpatients
Tuberculosis
Therapeutics
Safety
Costs and Cost Analysis

Keywords

  • Antituberculosis therapy
  • Multidrug-resistant
  • New drugs
  • Tuberculosis

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

New antituberculosis drugs : From clinical trial to programmatic use. / Gualano, Gina; Capone, Susanna; Matteelli, Alberto; Palmieri, Fabrizio.

In: Infectious Disease Reports, Vol. 8, No. 2, 2016, p. 43-49.

Research output: Contribution to journalArticle

@article{0337949b9acd49029dcc6ee064509e2d,
title = "New antituberculosis drugs: From clinical trial to programmatic use",
abstract = "Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensitive disease, highlighting the need for of new drugs. For the first time in more than 50 years, two new anti-TB drugs were approved and released. Bedaquiline is a first-in-class diarylquinoline compound that showed durable culture conversion at 24 weeks in phase IIb trials. Delamanid is the first drug of the nitroimidazole class to enter clinical practice. Similarly to bedaquiline results of phase IIb studies showed increased sputum-culture conversion at 2 months and better final treatment outcomes in patients with MDR-TB. Among repurposed drugs linezolid and carbapenems may represent a valuable drug to treat cases of MDR and extensively drugresistant TB. The recommended regimen for MDR-TB is the combination of at least four drugs to which M. tuberculosis is likely to be susceptible for the duration of 20 months. Drugs are chosen with a stepwise selection process through five groups on the basis of efficacy, safety, and cost. Clinical phase III trials on new regimen are ongoing that could prove transformative against MDR-TB, by being shorter (six months), simpler (an alloral regimen) and safer than current standard therapy. It is fundamental that the adoption of the new drugs is done responsibly to avoid inappropriate use. Concentration of inpatient MDR-TB treatment in specialized centers could be considered in countries with low numbers of cases in order to provide appropriate clinical case management and to prevent emergence of drug resistance.",
keywords = "Antituberculosis therapy, Multidrug-resistant, New drugs, Tuberculosis",
author = "Gina Gualano and Susanna Capone and Alberto Matteelli and Fabrizio Palmieri",
year = "2016",
doi = "10.4081/idr.2016.6569",
language = "English",
volume = "8",
pages = "43--49",
journal = "Infectious Disease Reports",
issn = "2036-7430",
publisher = "PagePress",
number = "2",

}

TY - JOUR

T1 - New antituberculosis drugs

T2 - From clinical trial to programmatic use

AU - Gualano, Gina

AU - Capone, Susanna

AU - Matteelli, Alberto

AU - Palmieri, Fabrizio

PY - 2016

Y1 - 2016

N2 - Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensitive disease, highlighting the need for of new drugs. For the first time in more than 50 years, two new anti-TB drugs were approved and released. Bedaquiline is a first-in-class diarylquinoline compound that showed durable culture conversion at 24 weeks in phase IIb trials. Delamanid is the first drug of the nitroimidazole class to enter clinical practice. Similarly to bedaquiline results of phase IIb studies showed increased sputum-culture conversion at 2 months and better final treatment outcomes in patients with MDR-TB. Among repurposed drugs linezolid and carbapenems may represent a valuable drug to treat cases of MDR and extensively drugresistant TB. The recommended regimen for MDR-TB is the combination of at least four drugs to which M. tuberculosis is likely to be susceptible for the duration of 20 months. Drugs are chosen with a stepwise selection process through five groups on the basis of efficacy, safety, and cost. Clinical phase III trials on new regimen are ongoing that could prove transformative against MDR-TB, by being shorter (six months), simpler (an alloral regimen) and safer than current standard therapy. It is fundamental that the adoption of the new drugs is done responsibly to avoid inappropriate use. Concentration of inpatient MDR-TB treatment in specialized centers could be considered in countries with low numbers of cases in order to provide appropriate clinical case management and to prevent emergence of drug resistance.

AB - Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensitive disease, highlighting the need for of new drugs. For the first time in more than 50 years, two new anti-TB drugs were approved and released. Bedaquiline is a first-in-class diarylquinoline compound that showed durable culture conversion at 24 weeks in phase IIb trials. Delamanid is the first drug of the nitroimidazole class to enter clinical practice. Similarly to bedaquiline results of phase IIb studies showed increased sputum-culture conversion at 2 months and better final treatment outcomes in patients with MDR-TB. Among repurposed drugs linezolid and carbapenems may represent a valuable drug to treat cases of MDR and extensively drugresistant TB. The recommended regimen for MDR-TB is the combination of at least four drugs to which M. tuberculosis is likely to be susceptible for the duration of 20 months. Drugs are chosen with a stepwise selection process through five groups on the basis of efficacy, safety, and cost. Clinical phase III trials on new regimen are ongoing that could prove transformative against MDR-TB, by being shorter (six months), simpler (an alloral regimen) and safer than current standard therapy. It is fundamental that the adoption of the new drugs is done responsibly to avoid inappropriate use. Concentration of inpatient MDR-TB treatment in specialized centers could be considered in countries with low numbers of cases in order to provide appropriate clinical case management and to prevent emergence of drug resistance.

KW - Antituberculosis therapy

KW - Multidrug-resistant

KW - New drugs

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84992725838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992725838&partnerID=8YFLogxK

U2 - 10.4081/idr.2016.6569

DO - 10.4081/idr.2016.6569

M3 - Article

VL - 8

SP - 43

EP - 49

JO - Infectious Disease Reports

JF - Infectious Disease Reports

SN - 2036-7430

IS - 2

ER -